Immune-related myasthenia gravis is a rare, disabling, and potentially fatal adverse event of immune checkpoint inhibitor treatment. It is important to identify and manage it promptly. We present two cases of immune-related de novo myasthenia gravis observed at the Modena Cancer Center in two elderly patients treated with two anti-PD-1 monoclonal antibodies: cemiplimab and nivolumab.
Cemiplimab- and nivolumab-induced myasthenia gravis: two clinical cases / Canino, F.; Pugliese, G.; Baldessari, C.; Greco, S.; Depenni, R.; Dominici, M.. - In: TUMORI. - ISSN 0300-8916. - 107:6(2021), pp. NP123-NP126. [10.1177/03008916211040559]
Cemiplimab- and nivolumab-induced myasthenia gravis: two clinical cases
Canino F.;Pugliese G.;Baldessari C.;Greco S.;Depenni R.;Dominici M.
2021
Abstract
Immune-related myasthenia gravis is a rare, disabling, and potentially fatal adverse event of immune checkpoint inhibitor treatment. It is important to identify and manage it promptly. We present two cases of immune-related de novo myasthenia gravis observed at the Modena Cancer Center in two elderly patients treated with two anti-PD-1 monoclonal antibodies: cemiplimab and nivolumab.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
